Dai-kenchu-to Enhances Accelerated Small Intestinal Movement.

Satoh, Kaneo; Kase, Yoshio; Hayakawa, Terumasa; Murata, Pin; Ishige, Atsushi; Sasaki, Hiroshi

doi:10.1248/bpb.24.1122

Cited by 42 publications

(39 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The rapid and direct action of these ingredients on intestinal epithelial cells, lymphocytes, enteric nerves, and smooth muscle cells are involved in TU‐100's vasodilatory and prokinetic effects (Satoh et al. 2001; Murata et al. 2002; Kito and Suzuki 2006; Tokita et al.…”

Section: Introductionmentioning

confidence: 99%

Daikenchuto (TU‐100) shapes gut microbiota architecture and increases the production of ginsenoside metabolite compound K

Hasebe

Ueno

Musch

et al. 2016

Pharmacology Res & Perspec

View full text Add to dashboard Cite

Many pharmaceutical agents not only require microbial metabolism for increased bioavailability and bioactivity, but also have direct effects on gut microbial assemblage and function. We examined the possibility that these actions are not mutually exclusive and may be mutually reinforcing in ways that enhance long‐term of these agents. Daikenchuto, TU‐100, is a traditional Japanese medicine containing ginseng. Conversion of the ginsenoside Rb1 (Rb1) to bioactive compound K (CK) requires bacterial metabolism. Diet‐incorporated TU‐100 was administered to mice over a period of several weeks. T‐RFLP and 454 pyrosequencing were performed to analyze the time‐dependent effects on fecal microbial membership. Fecal microbial capacity to metabolize Rb1 to CK was measured by adding TU‐100 or ginseng to stool samples to assess the generation of bioactive metabolites. Levels of metabolized TU‐100 components in plasma and in stool samples were measured by LC‐MS/MS. Cecal and stool short‐chain fatty acids were measured by GC‐MS. Dietary administration of TU‐100 for 28 days altered the gut microbiota, increasing several bacteria genera including members of Clostridia and Lactococcus lactis. Progressive capacity of microbiota to convert Rb1 to CK was observed over the 28 days administration of dietary TU‐100. Concomitantly with these changes, increases in all SCFA were observed in cecal contents and in acetate and butyrate content of the stool. Chronic consumption of dietary TU‐100 promotes changes in gut microbiota enhancing metabolic capacity of TU‐100 and increased bioavailability. We believe these findings have broad implications in optimizing the efficacy of natural compounds that depend on microbial bioconversion in general.

show abstract

Section: Introductionmentioning

confidence: 99%

Daikenchuto (TU‐100) shapes gut microbiota architecture and increases the production of ginsenoside metabolite compound K

Hasebe

Ueno

Musch

et al. 2016

Pharmacology Res & Perspec

View full text Add to dashboard Cite

show abstract

“…Previous pharmacological studies have suggested that DKT and its ingredients have a wide variety of biological effects, including stimulation of gastrointestinal motility [7,10,11,[12][13][14], increases in intestinal and colonic blood flow [15][16][17], stimulation of motilin, vasoactive intestinal peptide, 5-hydroxytryptamine (serotonin), Calcitonin GeneRelated Peptide (CGRP) and substance P release [16,18-20,], contraction and relaxation of intestinal smooth muscle [21,22], improvement of postoperative bowel motility, ileus and adhesive obstruction [23][24][25][26], anti-inflammatory effects [27] and suppression of bacterial translocation possibly mediated by ginseng ingredients [28]. Thus, basic and clinical evidence-based studies are establishing support for the use of DKT worldwide.…”

Section: Introductionmentioning

confidence: 99%

Safety and efficacy of Dai-kenchu-to in postoperative infants with gastroschisis

Otake¹,

Uchida²,

Koike³

et al. 2012

OJPed

View full text Add to dashboard Cite

Purpose: Intestinal dysfunction is a major problem after gastroschisis repair, and causes poor oral intake and poor body weight gain in infants with gastroschisis. Dai-kenchu-to (DKT) is often used in the treatment of gastrointestinal dysfunction in Japan. The purpose of this study was to analyze the effect of DKT on infants with uncomplicated gastroschisis. Methods: In this retrospective cohort study from 1991 to 2009, we assessed 16 infants with uncomplicated gastroschisis. Eight infants received 0.3 g/kg/day of DKT for 12 months (group 1) and 8 infants did not receive DKT (group 2). We analyzed their body weight as an indicator of the effect of DKT. Results: There were no significant differences in the background characteristics. The body weight of group 1 was significantly increased at the ages of 9 months (p = 0.0348) and 12 months (p = 0.0097), compared with group 2. Multivariate analyses revealed that only DKT administration had a significant impact on body weight gain at the ages of 9 months (p = 0.0201) and 12 months (p = 0.0111). No side effects related to DKT were reported. Conclusion: DKT administration might worksafely and effectively for improvingthe body weight gain in infants with uncomplicated gastroschisis.

show abstract

“…DKT has been shown to accelerate delayed intestinal transit induced by intestinal manipulation and/or morphine administration Fukuda et al, 2006;Tokita et al, 2007b) presumably via the stimulation of acetylcholine release and serotonin receptors, 5-HT3R and 5-HT4R (Shibata et al, 1999;Satoh et al, 2001b;Tokita et al, 2007b). On the other hand, DKT has been shown to suppress the overactivity of intestines induced by several stimuli, which may relate to its relaxing effects on the intestinal smooth muscle (Satoh et al, 2001c). Recent studies have addressed the possibility that DKT increases intestinal blood flow and ameliorates colitis via calcitonin gene-related peptide and/or adrenomedullin Kono et al, 2008).…”

Section: Introductionmentioning

confidence: 99%

Profiling of the Compounds Absorbed in Human Plasma and Urine after Oral Administration of a Traditional Japanese (Kampo) Medicine, Daikenchuto

Iwabu¹,

Watanabe²,

Hirakura³

et al. 2010

Drug Metab Dispos

View full text Add to dashboard Cite

ABSTRACT:Daikenchuto (DKT), a pharmaceutical-grade traditional Japanese (Kampo) medicine, has been widely used for the treatment of various gastrointestinal disorders including postoperative ileus and has been integrated into the modern medical care system in Japan as a prescription drug. DKT is a multiherbal medicine consisting of Japanese pepper (zanthoxylum fruit), processed ginger, and ginseng with maltose as an additive. Despite substantial research on the pharmacological activities of DKT and its ingredients, the lack of studies on absorption, distribution, metabolism, and excretion of DKT has made it difficult to obtain a consistent picture of its mechanism of action. In the present study, we constructed an analysis procedure consisting of seven conditions of liquid chromatography and mass spectrometric analysis, which enabled the identification of 44 ingredients of DKT component herbs. We investigated the plasma and urine profiles of these ingredients 0.5 to 8 h after oral administration of 15.0 g of DKT in four healthy volunteers. The results indicated that 1) hydroxy-␣-sanshool and [6]-shogaol, the prominent peaks in plasma derived from Japanese pepper and ginger, respectively, were detected at 0.5 h and thereafter decreased throughout the sampling period; 2) ginsenoside Rb 1 , a prominent peak derived from ginseng, increased gradually during the sampling period; 3) glucuronide conjugates of hydroxy-sanshools, shogaols, and gingerols were detected in plasma and urine; and 4) no obvious differences between samples from the two male and the two female individuals were observed. These results provide a strong basis for future studies on pharmacokinetics and pharmacology of DKT.

show abstract

Dai-kenchu-to Enhances Accelerated Small Intestinal Movement.

Cited by 42 publications

References 26 publications

Daikenchuto (TU‐100) shapes gut microbiota architecture and increases the production of ginsenoside metabolite compound K

Daikenchuto (TU‐100) shapes gut microbiota architecture and increases the production of ginsenoside metabolite compound K

Safety and efficacy of Dai-kenchu-to in postoperative infants with gastroschisis

Profiling of the Compounds Absorbed in Human Plasma and Urine after Oral Administration of a Traditional Japanese (Kampo) Medicine, Daikenchuto

Contact Info

Product

Resources

About